Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1462 • 2016 ACR/ARHP Annual Meeting
Magnesium Is a New Mediator Arthritis Severity and Joint Damage
Teresina Laragione, Nasim Azizgolshani, Carolyn Harris, Erjing Gao and Percio Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Given the effects of magnesium supplementation in suppressing components of the innate immunity in short-term studies, we examined the effect of dietary magnesium modifications…
Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting
Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Alain Saraux⁹, Thierry Schaeverbeke¹⁰, Jean Sibilia¹¹, Martin Soubrier¹², Olivier Vittecoq^13,14, Elodie Perrodeau¹⁵, Philippe Ravaud¹⁶, Xavier Mariette¹⁷ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Rheumatology, Paris Descartes University, Paris, France, ⁸Rheumatology, University Hospital, Lille, France, ⁹Rheumatology, Brest University Hospital, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹³Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁴Rheumatology, Rouen University Hospital, Rouen, France, ¹⁵Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁶Epidemiologist, PARIS, France, ¹⁷Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…
Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting
Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Alain Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, RENE MARC FLIPO⁷, Olivier Vittecoq⁸, Thierry Schaeverbeke⁹, Isabelle Pane¹⁰, Jean Sibilia¹¹, Xavier Mariette¹² and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hotel Dieu, PARIS, France, ³Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁹Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁰Epidemiology, Hotel Dieu, Paris, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…
Abstract Number: 364 • 2016 ACR/ARHP Annual Meeting
Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density
Rashmi ranjan Sahoo Sr.¹, Urmila Dhakad², Siddharth K. Das³, Ragini Srivastava⁴, Saumya Ranjan Tripathy⁵, Durgesh Srivastava⁶ and Harikrishnan Velayudhan⁷, ¹Rheumatology, King George Medical University, Lucknow, India, ²Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, ³Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, ⁴Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, ⁵KGMU, Lucknow, India, Lucknow, India, ⁶Rheumatology, King Georges Medical Univesity, Lucknow, India, ⁷Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India
Background/Purpose: Sclerostin, an osteocyte secreted protein encoded by SOST gene, is an important regulator of Wnt pathway. It prevents bone formation by blocking Wnt binding…
Abstract Number: 1493 • 2016 ACR/ARHP Annual Meeting
Screening Patterns for Hyperlipidemia Among Patients with Rheumatoid Arthritis Based on Patterns of Care from By Primary Care Physicians, Rheumatologists or Both
Iris Navarro-Millán¹, Shuo Yang², Lang Chen², Huifeng Yun³, Christie M. Bartels⁴, Aprajita Jagpal¹, Andrea Cherrington⁵, Liana Fraenkel⁶, Monika M. Safford⁷ and Jeffrey Curtis⁸, ¹Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Yale University School of Medicine, New Haven, CT, ⁷Weill Cornell Medical College, New York, NY, ⁸Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Coronary heart disease (CHD) is increased among patients with rheumatoid arthritis (RA). Limited data suggest that there is a screening gap for hyperlipidemia, a…
Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Laurent Chanroux and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
Abstract Number: 2628 • 2016 ACR/ARHP Annual Meeting
Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country
I Louw¹, M Ally², DC Janse van Rensburg², E Van Duuren³, D Nel³, H Miller-Janson⁴, M de Necker⁴, JC de Beer⁴ and H Duvenhage⁵, ¹Panorama Medical Centre, Cape Town, South Africa, ²University of Pretoria, Pretoria, South Africa, ³Jacaranda Hospital, Pretoria, South Africa, ⁴HEXOR (PTY) Ltd, Pretoria, South Africa, ⁵Bristol-Myers Squibb, Johannesburg, South Africa
Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…
Abstract Number: 489 • 2016 ACR/ARHP Annual Meeting
Early Detection of Inflammatory Arthritis: The Role of Musculoskeletal Symptoms, Infections and Rheumatoid Arthritis-Related Comorbidities in Primary Care
Marian van Beers-Tas¹, Markus Nielen², Joke C. Korevaar² and Dirkjan van Schaardenburg³, ¹Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, ²NIVEL (Netherlands Institute for Health Services Research), Utrecht, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
ACR ABSTRACT 2016 Early detection of inflammatory arthritis: the role of musculoskeletal symptoms, infections and rheumatoid arthritis-related comorbidities in primary care Background/Purpose: Rheumatoid arthritis…
Abstract Number: 1506 • 2016 ACR/ARHP Annual Meeting
One Third of Patients with Established Rheumatoid Arthritis (RA) Are Correctly Vaccinated Against Influenza and Pneumococcus and This Is Increasing: 3 Year Longitudinal Assessment of 776 Patients
Laure Gossec¹, Martin Soubrier², Frantz Foissac³, Anna Molto⁴, Thomas Bardin⁵, Francis Berenbaum⁶, Alain Cantagrel⁷, Marie Hélène Cerato⁸, Gerard H. Chales⁹, Isabelle Chary-Valckenaere¹⁰, Bernard Combe¹¹, Emmanuelle Dernis Labous¹², Liana Euller-Ziegler¹³, Rene-Marc Flipo¹⁴, Philippe Gaudin¹⁵, Melanie Gilson¹⁶, Sandrine Guis¹⁷, Xavier Mariette¹⁸, Gaël Mouterde¹⁹, Sophie Pouplin²⁰, Pascal Richette²¹, Alain Saraux²², Thierry Schaeverbeke²³, Jean Sibilia²⁴, Françoise Fayet²⁵ and Maxime Dougados²⁶, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³COMEDRA working group, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Hôpital Lariboisière, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Purpan Hospital, Toulouse, France, ⁸University Hospital, Toulouse, France, ⁹CHU RENNES, Rennes, France, ¹⁰University Hospital, Nancy, France, ¹¹Lapeyronie Hospital, Montpellier, France, ¹²Le Mans Hospital, Le Mans, France, ¹³Rheumatology, Nice, France, ¹⁴Rheumatology, University Hospital, Lille, France, ¹⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ¹⁶Hopital Sud, Grenoble, France, ¹⁷Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, ¹⁸Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁹Rheumatology Department, Hopital Lapeyronie, Montpellier, France, ²⁰Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²¹Rhumatologie, Hôpital Lariboisière, Paris, France, ²²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ²³Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁵Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ²⁶Cochin Hospital and Paris 05 University, Paris, France
Background/Purpose: Influenza and pneumococcal vaccinations are recommended in all patients with RA. However, it is well known that a gap exists between recommendations and their…
Abstract Number: 2448 • 2016 ACR/ARHP Annual Meeting
Contraceptive Methods in Women with Rheumatoid Arthritis
Megan E. B. Clowse, Gary McDaniel and Amanda M. Eudy, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Women with rheumatoid arthritis (RA) often take medications to control disease activity that, should a woman become pregnant, may increase the risk of poor…
Abstract Number: 3015 • 2016 ACR/ARHP Annual Meeting
The Good, the Bad and the Ugly – Refractory Rheumatoid Arthritis in 2016
Manuel Unger¹, Farideh Alasti², Gabriela Supp², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is characterised by the presence of a progressively destructive joint inflammation. Even in times of modern therapeutics, a subgroup of patients…
Abstract Number: 498 • 2016 ACR/ARHP Annual Meeting
Higher Serum Heavy Metals Concentrations Are Associated with Rheumatoid Arthritis : A Study of the Korean National Health and Nutrition Examination Survey (KNHANES)
Sang Hyun Joo¹, Dong Jin Go^2,3, Eun Young Ahn³, Hyun Mi Kwon³, Joongyub Lee⁴ and Yeong Wook Song^5,6, ¹Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, The Republic of, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, The Republic of, ⁴Division of Clinical Epidemiology Medical Research Collaborating Center Biomedical Research Institution, Seoul National University Hospital, Seoul, Korea, The Republic of, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁶1Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, The Republic of
Background/Purpose: The heavy metal Cadmium (Cd) may contribute to the high risk of developing rheumatoid arthritis (RA) through the cigarette smoking and occupational exposure including…
Abstract Number: 1529 • 2016 ACR/ARHP Annual Meeting
Serum Levels of P-Glycoprotein Are Associated with Disease Activity in Rheumatoid Arthritis
Edsaul Emilio Perez-Guerrero¹, Jorge Ivan Gamez-Nava², Ernesto German Cardona-Muñoz³, Jose Francisco Muñoz-Valle⁴, Paulina Hernandez-Cuervo^1,5, David Bonilla-Lara^6,7, Ana Miriam Saldaña-Cruz⁸, Nicte Selene Fajardo-Robledo⁹, Silvia Elena Totsuka-Sutto¹⁰, Ana Rosa Rincon-Sanchez⁷, David Cardona-Muller³ and Laura del Carmen Gonzalez-Lopez⁶, ¹Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ²Unidad de Investigación Biomédica 02 (Unidad de Investigacion en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituo Mexicano del Seguro Social, Guadalajara, Mexico, ³Departamento de Fisiología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, ⁴Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Programa de Doctorado en Ciencias de la Salud Pública, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara. Guadalajara, Jalisco, México., Guadalajara, Mexico, ⁶Departamento Medicina Interna-Reumatología, Instituto Mexicano del Seguro Social, Hospital General Regional 110, Jalisco, Mexico, ⁷Doctorado en Farmacología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico, ⁸Centro Universitario de Investigación Biomédica. Universidad de Colima, Colima, Mexico, ⁹Laboratorio de Investigación y Desarrollo Farmacéutico, Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e Ingenierias, Jalisco, Mexico, ¹⁰Unidad de Investigación Cardiovascular, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Background/Purpose: Patients with rheumatoid arthritis (RA) exert a wide variety of therapeutic responses to disease controlling anti-rheumatic drugs (DMARDs). P-glycoprotein (P-Gp) is involved in treatment…
Abstract Number: 2478 • 2016 ACR/ARHP Annual Meeting
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
LR Harrold¹, E Alemao², HJ Litman³, SE Connolly⁴, S Kelly², W Hua³, L Rosenblatt², S Rebello⁵ and JM Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Poor prognostic factors can determine the extent of disease progression, disability and treatment outcomes in patients (pts) with RA. It is currently unknown whether…
Abstract Number: 3021 • 2016 ACR/ARHP Annual Meeting
Frequency of Arthralgia, Seropositivity, and Seropositive Arthralgia and Their Association with Development of Rheumatoid Arthritis in a Cohort of Indigenous North Americans with or without a First Degree Relative with Rheumatoid Arthritis
Elizabeth Ferucci¹, Carol Hitchon², Irene Smolik³, David Robinson³ and Hani El-Gabalawy⁴, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: Anti-citrullinated peptide antibodies and/or rheumatoid factor (RF) in the setting of arthralgia (“seropositive arthralgia”) has been associated with a high risk of development of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.